Vimarsana
Biggest News Aggregation in the World

Page 35 - Institutional Equities News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Institutional Equities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Institutional Equities Today - Breaking & Trending Today

Bharti Airtel: Telco revenues may surge to Rs 2.78 lakh crore in FY25, ET Telecom - Vimarsana News

Bharti Airtel: Telco revenues may surge to Rs 2.78 lakh crore in FY25, ET Telecom

Bharti Airtel: Even in the absence of rate hikes, telecom sector revenues this financial year are expected to touch Rs 2.46 lakh crore, far exceeding the FY16 levels, amid strong appetite for 4G services and an improving subscriber mix, showed an analysis of Trai data by global brokerage, CLSA. The estimated jump in sectoral revenues (in absolute terms) is even more spectacular at 68% between FY17, when Jio entered the fray, and FY25.

pb fintech share price: Policybazaar shares jump 7% on IRDAI's license upgrade for PB Fintech's arm - Vimarsana News

pb fintech share price: Policybazaar shares jump 7% on IRDAI's license upgrade for PB Fintech's arm

The insurance regulator upgraded the license of the company's wholly-owned subsidiary Policybazaar Insurance Brokers Private Limited to 'Composite Insurance Broker' from 'Direct Insurance Broker'

Telco revenues may surge to Rs 2.78 lakh crore in FY25 - Vimarsana News

Telco revenues may surge to Rs 2.78 lakh crore in FY25

Revenues stood at ₹1.7 lakh crore in FY16 with the sector having more than 10 private companies. This was before Reliance Jio made its debut the following year. Revenues are expected to touch ₹2.78 lakh crore in FY25 in an industry comprising only three private operators - Jio, Bharti Airtel and Vodafone Idea (Vi).

BPCL, HPCL to account 31% of increment FY24 Nifty profit; OMCs may drag numbers in FY25! - Vimarsana News

BPCL, HPCL to account 31% of increment FY24 Nifty profit; OMCs may drag numbers in FY25!

BPCL’s reported GRM was above Kotak's estimate, while its implied marketing margin was below its estimate. HPCL's Q3 missed Kotak's Ebitda estimate due to a lower-than-expected marketing margin.

Natco Pharma stock up 18% today, 26% in 4-day rally. Nuvama shares target price - Vimarsana News

Natco Pharma stock up 18% today, 26% in 4-day rally. Nuvama shares target price

Natco Pharma share price target: Nuvama has raised its FY24E and FY25 EPS estimates for Natco Pharma by 21 per cent and 12 per cent, respectively, to factor in the beat, higher gRevlimid and lower tax; target at Rs 1,055.